InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Announcements

Current share price for VFY : $2.310 0.07 (2.94%)+

ASX company news and announcements for Vitrafy Life Sciences Limited (VFY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitrafy Life Sciences Limited (VFY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitrafy Life Sciences Limited (VFY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitrafy Life Sciences Limited (VFY)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$144 Results of 2026 Annual General Meeting 17 Nov 2026 3:42PM $2.770 $2.310 fallen by 16.61%
$144 2026 Annual General Meeting Addresses & Presentation 17 Nov 2026 12:27PM $2.460 $2.310 fallen by 6.10%
$144 Release of Securities from Mandatory Escrow 9 Nov 2026 12:42PM $2.450 $2.310 fallen by 5.71%
$144 Quarterly Investor Briefing Presentation 28 Oct 2026 8:17AM $2.410 $2.310 fallen by 4.15%
$144 Q1 FY27 Quarterly Activities Report and Appendix 4C 28 Oct 2026 8:17AM $2.410 $2.310 fallen by 4.15%
$144 Vitrafy Q1 FY27 Investor Briefing 26 Oct 2026 1:49PM $2.480 $2.310 fallen by 6.85%
$144 Application for quotation of securities - VFY 20 Oct 2026 9:10AM $2.710 $2.310 fallen by 14.76%
$144 Appointment of Chief Financial Officer 20 Oct 2026 8:24AM $2.710 $2.310 fallen by 14.76%
$144 2026 Notice of Annual General Meeting 16 Oct 2026 8:22AM $2.870 $2.310 fallen by 19.51%
$144 Investor Roadshow Presentation 7 Oct 2026 8:21AM $3.510 $2.310 fallen by 34.19%
$144 Change to CEO Remuneration and Employment Terms 7 Oct 2026 8:21AM $3.510 $2.310 fallen by 34.19%
$144 Vitrafy enters partnership with Versiti Blood Health 30 Sep 2026 12:02PM $3.330 $2.310 fallen by 30.63%
$144 S&P DJI Announces September 2026 Quarterly Rebalance 4 Sep 2026 5:10PM $3.870 $2.310 fallen by 40.31%
$144 Vitrafy enters U.S. Cell & Gene Therapy Market 2 Sep 2026 9:17AM $3.860 $2.310 fallen by 40.16%
$144 FY26 Corporate Governance Statement 4 Aug 2026 8:23AM $3.700 $2.310 fallen by 37.57%
$144 FY26 Appendix 4G 4 Aug 2026 8:23AM $3.700 $2.310 fallen by 37.57%
$144 FY26 Full Year Results Presentation 4 Aug 2026 8:23AM $3.700 $2.310 fallen by 37.57%
$144 FY26 Appendix 4E and Annual Report 4 Aug 2026 8:22AM $3.700 $2.310 fallen by 37.57%
$144 Vitrafy FY26 Investor Briefing 3 Aug 2026 1:36PM $3.690 $2.310 fallen by 37.40%
$144 Q4 FY26 Quarterly Activities Report and Appendix 4C 29 Jul 2026 8:29AM $3.090 $2.310 fallen by 25.24%
$144 Vitrafy enters a partnership with Hoxworth Blood Center 23 Jul 2026 8:29AM $2.810 $2.310 fallen by 17.79%
$144 Application for quotation of securities - VFY 22 Jul 2026 8:26AM $2.810 $2.310 fallen by 17.79%
$144 Notification of cessation of securities - VFY 13 Jul 2026 11:43AM $2.900 $2.310 fallen by 20.34%
$144 Application for quotation of securities - VFY 10 Jul 2026 9:05AM $3.010 $2.310 fallen by 23.26%
$144 Change of Director's Interest Notice - Correction 9 Jul 2026 9:31AM $2.960 $2.310 fallen by 21.96%

1 - 25 of 131 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.